Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

NCT02472795 is registered in ClinicalTrials.gov with Viatris Innovation GmbH as lead sponsor.

NCT NCT02472795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02472795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Lead sponsor
Viatris Innovation GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
June 1, 2015
Completion date
February 28, 2017
Enrollment
105 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus